Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$153.41 USD

153.41
3,224,670

-3.19 (-2.04%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $153.41 0.00 (0.00%) 6:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Baxter (BAX) Q4 Earnings Miss Estimates, FY23 Outlook Weak

by Zacks Equity Research

Baxter's (BAX) fourth-quarter results reflect impact of additional sales from the legacy Hilrom's business acquired in 2021. Ongoing macroeconomic challenges hurt earnings significantly.

Zacks Equity Research

3 Reasons to Retain NextGen (NXGN) Stock in Your Portfolio

by Zacks Equity Research

NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.

Zacks Equity Research

Haemonetics (HAE) Q3 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

In the fiscal third quarter, Haemonetics (HAE) incurs higher research and development costs, primarily due to increased investments in product innovation.

Zacks Equity Research

CVS Health (CVS) Q4 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

CVS Health's (CVS) Retail/LTC segment revenues rise on increased prescription and front store volume, pharmacy drug mix and brand inflation.

Zacks Equity Research

Inspire Medical (INSP) Q4 Earnings, Revenues Top Estimates

by Zacks Equity Research

Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the fourth quarter.

Derek Lewis headshot

This Portfolio of 3 Dividend Aristocrats Pays Monthly

by Derek Lewis

By targeting companies that pay out dividends in different months, investors can construct a portfolio that allows them to reap monthly income. Who doesn't love payday?

Zacks Equity Research

Here is Why Growth Investors Should Buy Cardinal (CAH) Now

by Zacks Equity Research

Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Catalent (CTLT) Q2 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Catalent (CTLT) records lower revenues in both segments in its second-quarter fiscal 2023, resulting in overall soft performance.

Zacks Equity Research

Surmodics (SRDX) Q1 Earnings Top Estimates, FY23 View Revised

by Zacks Equity Research

Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust Medical Device revenues.

Zacks Equity Research

Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for SPYD

Zacks Equity Research

LabCorp's (LH) New Launches, Planned Spinoff to Aid Growth

by Zacks Equity Research

In terms of portfolio enhancement, LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to advance in life-changing treatments for cancer and other diseases.

Zacks Equity Research

Avantor (AVTR) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Despite Avantor's (AVTR) robust core organic sales across its segments, it reports an overall soft Q4 performance.

Zacks Equity Research

Cardinal Health, Inc. (CAH) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Zacks.com users have recently been watching Cardinal (CAH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Zacks Industry Outlook Highlights McKesson, AmerisourceBergen, LabCorp, Cardinal Health and Merit Medical

by Zacks Equity Research

McKesson, AmerisourceBergen, LabCorp, Cardinal Health and Merit Medical have been highlighted in this Industry Outlook article.

Zacks Equity Research

Cardinal (CAH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Cardinal (CAH) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Cardinal Health (CAH) is a Top-Ranked Value Stock: Should You Buy?

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Company News for Feb 3, 2023

by Zacks Equity Research

Companies in The news Are: META, BMY, PH, CAH.

Indrajit Bandyopadhyay headshot

5 Dental Supplies Stocks to Buy Amid Recovering Prospects

by Indrajit Bandyopadhyay

Here, we discuss five stocks from the Dental Supplies industry that are likely to create wealth for investors - MCK, ABC, LH, CAH and MMSI.

Zacks Equity Research

Cardinal Health (CAH) Q2 Earnings Top, EPS Outlook Raised

by Zacks Equity Research

Cardinal Health's (CAH) fiscal second-quarter results benefit from the solid performance of the Pharmaceutical segment.

Zacks Equity Research

Hologic (HOLX) Q1 Earnings Beat Estimates, 2023 View Up

by Zacks Equity Research

Lower COVID-19 assays sales and supply chain challenges related to semiconductor chips dent Hologic's (HOLX) top line in Q1.

Zacks Equity Research

McKesson (MCK) Q3 Earnings Surpass Estimates, EPS View Up

by Zacks Equity Research

McKesson's (MCK) third-quarter fiscal 2023 results benefit from segmental growth.

Zacks Equity Research

Zacks.com featured highlights Archer-Daniels-Midland, Agilent Technologies, Republic Services, Deere and Cardinal Health

by Zacks Equity Research

Archer-Daniels-Midland, Agilent Technologies, Republic Services, Deere and Cardinal Health have been highlighted in this Screen of The Week article.

Zacks Equity Research

Cardinal Health (CAH) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Cardinal (CAH) delivered earnings and revenue surprises of 16.81% and 2.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AmerisourceBergen (ABC) Q1 Earnings Top, EPS View Raised

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal first-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.

Zacks Equity Research

What's in the Cards for Mesa Laboratories' (MLAB) Q3 Earnings?

by Zacks Equity Research

Continued strength in Mesa Laboratories' (MLAB) Clinical Genomics segment is expected to have driven up Q3 sales.